The Latest Cardiac and Vascular News
– Exclusive rights secured related to the development of a potential disease-modifying therapeutic for cardiovascular disease. CHICAGO, Dec. 19, 2024 /PRNewswire/ — Xentria, Inc. (Xentria), a clinical-stage biotherapeutics company focused on advancing drug development to address unmet…
TGD001 is being developed to offer patients with clotting disorders a faster, safer and more effective treatment than today’s standard of care – saving lives and reducing disability Following the Phase 1 safety study, TargED intends to further develop TGD001 in patients with AIS and iTTP…
December 18, 2024 07:35 AM Eastern Standard Time NEW YORK–(BUSINESS WIRE)–DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, today announced an expanded partnership with SHL Telemedicine (NASDAQ: SHLT) to integrate the SmartHeart® portable 12-lead ECG device across DocGo mobile health care units. […]
HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR, a clinical-stage medical device company, announced today, the successful completion of the first phase of the FDA Early Feasibility Study, with five patients receiving the BiVACOR Total Artificial Heart (TAH) between July and November 2024. The study evaluates the safety and performance of the BiVACOR TAH System […]
Pilot study testing innovative agent designed to provide guideline-concordant education believed to be the first clinical study to evaluate an AI Agent with actual AFib patients SAN DIEGO, Dec. 18, 2024 /PRNewswire/ — Lucia Health Guidelines announces the enrollment of the first eight…
BOSTON and SEATTLE, Dec. 18, 2024 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat or currently incurable diseases with significant unmet needs, today announced that its wholly owned preclinical subsidiary for disease modelling and drug discovery, Novoheart, has entered into a transformative partnership with Curi Bio Inc., a leader in preclinical screening technologies. This strategic collaboration integrates Novoheart’s industry-leading human Heart-in-a-Jar technology with Curi Bio’s advanced Pulse™ analytics platform, delivering an innovative solution for accelerated, high-content, human-based cardiac drug development.
December 17, 2024 03:09 PM Eastern Standard Time MARLBOROUGH, Mass.–(BUSINESS WIRE)–CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced the first series of patients treated with the investigational OptiShot™ Pulsed Field Ablation (PFA) System for the treatment of paroxysmal atrial fibrillation as part […]
MINNETONKA, Minn.–(BUSINESS WIRE)–AngioInsight, Inc., an innovator in medical imaging technologies, is pleased to announce the appointment of Scott Burger as its Chief Executive Officer (CEO). Scott brings over two decades of extensive leadership experience in the healthcare and medical technology sectors, positioning him perfectly to lead AngioInsight into its next […]
December 17, 2024 08:00 AM Eastern Standard Time MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a new publication in the Journal of Thoracic and Cardiovascular Surgery. This preclinical study demonstrates the advantages of the […]
SHERIDAN, Wyo., and AVENTURA, Fla., Dec. 17, 2024 /PRNewswire/ — Radin Health, a leading provider of advanced radiology AI-Powered solutions, proudly announces the overwhelming success of its All-in-One Radiology Workflow Management Solution at the Radiological Society of North America…
